Paper · 42881857

Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib.

Kawczak P and 1 other. J Clin Med, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib. Papers, record 42881857. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42881857

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib.
Journal: J Clin Med
Year: 2026
Publication types: Journal Article, Review
PubMed: https://pubmed.ncbi.nlm.nih.gov/42881857/
DOI: https://doi.org/10.3390/jcm15197396
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13665538/
The journal: https://conductscience.org/library/journal-index/101606588
Revised in PubMed: 2026-10-20

Source PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	Kind	ORCID iD
1	Kawczak P	Piotr		https://orcid.org/0000-0003-3902-2744
2	Bączek T	Tomasz

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References298

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	42,137,650	Hepatic Artery Infusion Chemotherapy for Cholangiocarcinoma in 2025.	Liver Cancer	2026	https://conductscience.org/library/papers/42137650	PubMed
2	37,710,362	FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions.	Expert Opin Pharmacother	2023	https://conductscience.org/library/papers/37710362	PubMed
3	32,168,869	New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.	Cells	2020	https://conductscience.org/library/papers/32168869	PubMed
4	42,293,741	Lipid nanoparticles and extracellular vesicles: emerging cell free therapeutic platforms for hepatobiliary cancers.	Front Cell Dev Biol	2026	https://conductscience.org/library/papers/42293741	PubMed
5	26,258,846	Genomic spectra of biliary tract cancer.	Nat Genet	2015	https://conductscience.org/library/papers/26258846	PubMed
6	39,438,389	Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma.	Target Oncol	2025	https://conductscience.org/library/papers/39438389	PubMed
7	30,905,548	Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.	Clin Colorectal Cancer	2019	https://conductscience.org/library/papers/30905548	PubMed
8	32,416,072	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.	Lancet Oncol	2020	https://conductscience.org/library/papers/32416072	PubMed
9	25,162,885	Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.	N Engl J Med	2014	https://conductscience.org/library/papers/25162885	PubMed
10	36,102,999	Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.	Cancer Chemother Pharmacol	2022	https://conductscience.org/library/papers/36102999	PubMed

1 to 10 of 298

See all 298 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42881857

GET https://conductscience.org/api/papers/v1/42881857/references?page=2

API reference For AI assistants